234 related articles for article (PubMed ID: 17641798)
1. Angiogenesis and c-erbB-2 (HER2/neu) overexpression status in primary breast cancer patients: an analysis of 158 needle core biopsies.
Vameşu S
Rom J Morphol Embryol; 2007; 48(2):121-9. PubMed ID: 17641798
[TBL] [Abstract][Full Text] [Related]
2. Angiogenesis and co-expressed of ER and c-erbB-2 (HER2/neu) protein in primary breast cancer patients: an analysis of 158 needle core biopsies.
Vameşu S
Rom J Morphol Embryol; 2008; 49(4):469-78. PubMed ID: 19050794
[TBL] [Abstract][Full Text] [Related]
3. Angiogenesis and progesterone receptor status in primary breast cancer patients: an analysis of 158 needle core biopsies.
Vameşu S
Rom J Morphol Embryol; 2007; 48(3):267-74. PubMed ID: 17914494
[TBL] [Abstract][Full Text] [Related]
4. Angiogenesis and tumor grading in primary breast cancer patients: an analysis of 158 needle core biopsies.
Vameşu S
Rom J Morphol Embryol; 2006; 47(3):251-7. PubMed ID: 17308684
[TBL] [Abstract][Full Text] [Related]
5. Angiogenesis and tumor histologic type in primary breast cancer patients: an analysis of 155 needle core biopsies.
Vameşu S
Rom J Morphol Embryol; 2008; 49(2):181-8. PubMed ID: 18516324
[TBL] [Abstract][Full Text] [Related]
6. Angiogenesis and ER/PR status in primary breast cancer patients: an analysis of 158 needle core biopsies.
Vameşu S
Rom J Morphol Embryol; 2007; 48(1):25-31. PubMed ID: 17502947
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
[TBL] [Abstract][Full Text] [Related]
8. Study of HER2/neu status in Qatari women with breast carcinoma.
Rasul KI; Mohammaed K; Abdalla AS; Chong-Lopez A; Ahmad MA; Al-Homsi MU; Al-Hassan AM; Al-Alosi AS; Bener A
Saudi Med J; 2003 Aug; 24(8):832-6. PubMed ID: 12939666
[TBL] [Abstract][Full Text] [Related]
9. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
10. HER2/neu expression in relation to clinicopathologic features of breast cancer patients.
Traina A; Agostara B; Marasà L; Calabrò M; Zarcone M; Carruba G
Ann N Y Acad Sci; 2006 Nov; 1089():159-67. PubMed ID: 17261764
[TBL] [Abstract][Full Text] [Related]
11. Do prognostic marker studies on core needle biopsy specimens of breast carcinoma accurately reflect the marker status of the tumor?
Jacobs TW; Siziopikou KP; Prioleau JE; Raza S; Baum JK; Hayes DF; Schnitt SJ
Mod Pathol; 1998 Mar; 11(3):259-64. PubMed ID: 9521472
[TBL] [Abstract][Full Text] [Related]
12. Expression of HER2/neu in primary and metastatic breast cancer.
Tuziak T; Olszewski WP; Olszewski W; Pieńkowski T
Pol J Pathol; 2001; 52(1-2):21-6. PubMed ID: 11505677
[TBL] [Abstract][Full Text] [Related]
13. HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process.
Vincent-Salomon A; Jouve M; Genin P; Fréneaux P; Sigal-Zafrani B; Caly M; Beuzeboc P; Pouillart P; Sastre-Garau X
Cancer; 2002 Apr; 94(8):2169-73. PubMed ID: 12001113
[TBL] [Abstract][Full Text] [Related]
14. The correlation of c-erbB-2 oncoprotein and established prognostic factors in human breast cancer.
Sütterlin MW; Haller A; Gassel AM; Peters K; Caffier H; Dietl J
Anticancer Res; 2000; 20(6D):5083-8. PubMed ID: 11326673
[TBL] [Abstract][Full Text] [Related]
15. Metaplastic breast carcinoma: clinical-pathologic characteristics and HER2/neu expression.
Barnes PJ; Boutilier R; Chiasson D; Rayson D
Breast Cancer Res Treat; 2005 May; 91(2):173-8. PubMed ID: 15868445
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients.
Xia W; Chen JS; Zhou X; Sun PR; Lee DF; Liao Y; Zhou BP; Hung MC
Clin Cancer Res; 2004 Jun; 10(11):3815-24. PubMed ID: 15173090
[TBL] [Abstract][Full Text] [Related]
17. Expression levels and clinical-pathological correlations of HER2/neu in primary and metastatic human breast cancer.
Stefano R; Agostara B; Calabrò M; Campisi I; Ravazzolo B; Traina A; Miele M; Castagnetta L
Ann N Y Acad Sci; 2004 Dec; 1028():463-72. PubMed ID: 15650272
[TBL] [Abstract][Full Text] [Related]
18. Her-2/neu oncogene expression in Puerto Rican females with breast cancer.
Peredo R; Sastre G; Serrano J; Hunter Mellado R
Cell Mol Biol (Noisy-le-grand); 2001 Sep; 47(6):1025-32. PubMed ID: 11785652
[TBL] [Abstract][Full Text] [Related]
19. Intratumoral heterogeneity of HER2/neu in breast cancer--a rare event.
Hanna W; Nofech-Mozes S; Kahn HJ
Breast J; 2007; 13(2):122-9. PubMed ID: 17319852
[TBL] [Abstract][Full Text] [Related]
20. Angiogenic potential of ductal carcinoma in situ (DCIS) of human breast.
Vogl G; Dietze O; Hauser-Kronberger C
Histopathology; 2005 Dec; 47(6):617-24. PubMed ID: 16324200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
